We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
Read MoreHide Full Article
Key Takeaways
Merck is looking to acquire Terns for $53 per share, valuing the deal at almost $6.7B equity.
Terns TERN-701, a leukemia drug candidate, showed strong early clinical response rates in studies.
Merck is ramping up merger and acquisition deals in recent times to offset Keytruda's 2028 patent loss.
Merck (MRK - Free Report) announced that it has entered into a definitive agreement to acquire California-based cancer biotech, Terns Pharmaceuticals (TERN - Free Report) , for $53.00 per share in cash or an estimated equity value of $6.7 billion.
The offer values the deal at about $5.7 billion after adjusting for cash.
Following the announcement of the acquisition, shares of Merck were up 2.6%. Terns' stock gained 5.7% yesterday.
Year to date, shares of Merck have risen 13.4% against the industry’s decrease of 4.9%.
Image Source: Zacks Investment Research
Shares of Terns have rallied 30.8% so far this year against the industry’s decrease of 0.6%.
Image Source: Zacks Investment Research
TERN Acquisition Can Boost Merck’s Cancer Pipeline
The impending acquisition will add Terns’ lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, to Merck’s hematology/cancer pipeline. The candidate is currently being evaluated in a phase I/II study for treating certain patients with chronic myeloid leukemia (CML).
Per the company, TERN-701 has shown promising results so far, with encouraging major and deep molecular response rates by week 24 in clinical studies. Based on this early data, management believes that, if successfully developed, TERN-701 could offer a differentiated treatment option for certain patients with CML.
TERN-701 has received an Orphan Drug designation from the FDA for treating CML.
The acquisition is expected to be closed in the second quarter of 2026, subject to customary closing conditions. It is likely to further strengthen and diversify MRK’s oncology pipeline.
The deal is expected to lead to a charge of around $5.8 billion, or roughly $2.35 per share, which will be reflected in Merck’s second-quarter and full-year 2026 GAAP and non-GAAP results.
MRK Eyes M&A Deal to Offset Keytruda’s Upcoming LOE
Merck has been on an acquisition spree in recent times, as it faces looming patent expiration of its blockbuster drug, PD-L1 inhibitor Keytruda, in 2028. Keytruda accounts for more than 50% of the company’s pharmaceutical sales.
Merck acquired Cidara Therapeutics for $9.2 billion in January 2026. The acquisition added CDTX’s lead pipeline candidate, CD388, a first-in-class long-acting, strain-agnostic antiviral agent, currently being evaluated in late-stage studies for the prevention of seasonal influenza in individuals at higher risk of complications.
Last year, Merck acquired Verona Pharma for around $10 billion, which added the latter’s lead drug Ohtuvayre, a novel, first-in-class maintenance treatment for chronic obstructive pulmonary disease, with multibillion-dollar commercial potential. Ohtuvayre's commercial launch is off to a solid start, backed by strong growth in new patient starts and total patients treated.
Merck believes new products like Ohtuvayre could drive long-term growth and help offset the revenue gap expected from Keytruda’s upcoming loss of exclusivity in 2028. Merck acquired cancer biotech, Harpoon Therapeutics, in 2024.
MRK & TERN’s Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold), while Terns has a Zacks Rank #2 (Buy).
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.32 to $6.36, while the same for 2027 have narrowed from $5.97 to $4.64. AMRN shares have risen 5.2% in the year-to-date period.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, with the average surprise being 51.29%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
Key Takeaways
Merck (MRK - Free Report) announced that it has entered into a definitive agreement to acquire California-based cancer biotech, Terns Pharmaceuticals (TERN - Free Report) , for $53.00 per share in cash or an estimated equity value of $6.7 billion.
The offer values the deal at about $5.7 billion after adjusting for cash.
Following the announcement of the acquisition, shares of Merck were up 2.6%. Terns' stock gained 5.7% yesterday.
Year to date, shares of Merck have risen 13.4% against the industry’s decrease of 4.9%.
Image Source: Zacks Investment Research
Shares of Terns have rallied 30.8% so far this year against the industry’s decrease of 0.6%.
Image Source: Zacks Investment Research
TERN Acquisition Can Boost Merck’s Cancer Pipeline
The impending acquisition will add Terns’ lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, to Merck’s hematology/cancer pipeline. The candidate is currently being evaluated in a phase I/II study for treating certain patients with chronic myeloid leukemia (CML).
Per the company, TERN-701 has shown promising results so far, with encouraging major and deep molecular response rates by week 24 in clinical studies. Based on this early data, management believes that, if successfully developed, TERN-701 could offer a differentiated treatment option for certain patients with CML.
TERN-701 has received an Orphan Drug designation from the FDA for treating CML.
The acquisition is expected to be closed in the second quarter of 2026, subject to customary closing conditions. It is likely to further strengthen and diversify MRK’s oncology pipeline.
The deal is expected to lead to a charge of around $5.8 billion, or roughly $2.35 per share, which will be reflected in Merck’s second-quarter and full-year 2026 GAAP and non-GAAP results.
MRK Eyes M&A Deal to Offset Keytruda’s Upcoming LOE
Merck has been on an acquisition spree in recent times, as it faces looming patent expiration of its blockbuster drug, PD-L1 inhibitor Keytruda, in 2028. Keytruda accounts for more than 50% of the company’s pharmaceutical sales.
Merck acquired Cidara Therapeutics for $9.2 billion in January 2026. The acquisition added CDTX’s lead pipeline candidate, CD388, a first-in-class long-acting, strain-agnostic antiviral agent, currently being evaluated in late-stage studies for the prevention of seasonal influenza in individuals at higher risk of complications.
Last year, Merck acquired Verona Pharma for around $10 billion, which added the latter’s lead drug Ohtuvayre, a novel, first-in-class maintenance treatment for chronic obstructive pulmonary disease, with multibillion-dollar commercial potential. Ohtuvayre's commercial launch is off to a solid start, backed by strong growth in new patient starts and total patients treated.
Merck believes new products like Ohtuvayre could drive long-term growth and help offset the revenue gap expected from Keytruda’s upcoming loss of exclusivity in 2028. Merck acquired cancer biotech, Harpoon Therapeutics, in 2024.
MRK & TERN’s Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold), while Terns has a Zacks Rank #2 (Buy).
Key Pick
A top-ranked stock in the biotech sector is Amarin (AMRN - Free Report) , carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.32 to $6.36, while the same for 2027 have narrowed from $5.97 to $4.64. AMRN shares have risen 5.2% in the year-to-date period.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, with the average surprise being 51.29%.